vs
Side-by-side financial comparison of Ellington Financial Inc. (EFC) and IRONWOOD PHARMACEUTICALS INC (IRWD). Click either name above to swap in a different company.
Ellington Financial Inc. is the larger business by last-quarter revenue ($78.2M vs $47.7M, roughly 1.6× IRONWOOD PHARMACEUTICALS INC). Ellington Financial Inc. runs the higher net margin — 28.9% vs -4.8%, a 33.7% gap on every dollar of revenue. On growth, Ellington Financial Inc. posted the faster year-over-year revenue change (8.7% vs -47.3%). Over the past eight quarters, Ellington Financial Inc.'s revenue compounded faster (1.8% CAGR vs -20.2%).
Ellington Management Group is an American hedge fund firm. As of June 2019, the firm was reportedly managing $8.5 billion in structured products and other credit instruments.
Ironwood Pharmaceuticals, Inc. is a publicly traded pharmaceutical company. It was originally called Microbia, Inc.
EFC vs IRWD — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $78.2M | $47.7M |
| Net Profit | $22.6M | $-2.3M |
| Gross Margin | — | — |
| Operating Margin | 7.4% | 14.3% |
| Net Margin | 28.9% | -4.8% |
| Revenue YoY | 8.7% | -47.3% |
| Net Profit YoY | -26.2% | -200.9% |
| EPS (diluted) | $0.10 | $0.01 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $78.2M | $47.7M | ||
| Q3 25 | $82.8M | $122.1M | ||
| Q2 25 | $92.5M | $85.2M | ||
| Q1 25 | $82.9M | $41.1M | ||
| Q4 24 | $72.0M | $90.5M | ||
| Q3 24 | $67.0M | $91.6M | ||
| Q2 24 | $91.2M | $94.4M | ||
| Q1 24 | $75.5M | $74.9M |
| Q4 25 | $22.6M | $-2.3M | ||
| Q3 25 | $29.5M | $40.1M | ||
| Q2 25 | $42.9M | $23.6M | ||
| Q1 25 | $31.6M | $-37.4M | ||
| Q4 24 | $30.7M | $2.3M | ||
| Q3 24 | $16.2M | $3.6M | ||
| Q2 24 | $52.3M | $-860.0K | ||
| Q1 24 | $26.9M | $-4.2M |
| Q4 25 | 7.4% | 14.3% | ||
| Q3 25 | 31.1% | 61.8% | ||
| Q2 25 | 38.3% | 53.2% | ||
| Q1 25 | 37.3% | -70.7% | ||
| Q4 24 | 28.0% | 34.8% | ||
| Q3 24 | 24.0% | 28.0% | ||
| Q2 24 | 52.8% | 26.5% | ||
| Q1 24 | 42.2% | 14.7% |
| Q4 25 | 28.9% | -4.8% | ||
| Q3 25 | 35.7% | 32.8% | ||
| Q2 25 | 46.4% | 27.7% | ||
| Q1 25 | 38.2% | -90.9% | ||
| Q4 24 | 42.6% | 2.5% | ||
| Q3 24 | 24.1% | 4.0% | ||
| Q2 24 | 57.4% | -0.9% | ||
| Q1 24 | 35.6% | -5.6% |
| Q4 25 | $0.10 | $0.01 | ||
| Q3 25 | $0.29 | $0.23 | ||
| Q2 25 | $0.45 | $0.14 | ||
| Q1 25 | $0.35 | $-0.23 | ||
| Q4 24 | $0.23 | $0.03 | ||
| Q3 24 | $0.19 | $0.02 | ||
| Q2 24 | $0.62 | $-0.01 | ||
| Q1 24 | $0.32 | $-0.03 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $201.9M | $215.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.8B | $-261.8M |
| Total Assets | $19.4B | $396.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $201.9M | $215.5M | ||
| Q3 25 | $184.8M | $140.4M | ||
| Q2 25 | $211.0M | $92.9M | ||
| Q1 25 | $203.3M | $108.5M | ||
| Q4 24 | $192.4M | $88.6M | ||
| Q3 24 | $217.7M | $88.2M | ||
| Q2 24 | $198.5M | $105.5M | ||
| Q1 24 | $187.5M | $121.5M |
| Q4 25 | — | — | ||
| Q3 25 | — | $199.5M | ||
| Q2 25 | — | $199.3M | ||
| Q1 25 | — | $199.2M | ||
| Q4 24 | — | $199.0M | ||
| Q3 24 | — | $198.8M | ||
| Q2 24 | — | $198.6M | ||
| Q1 24 | — | $398.3M |
| Q4 25 | $1.8B | $-261.8M | ||
| Q3 25 | $1.8B | $-264.2M | ||
| Q2 25 | $1.7B | $-308.2M | ||
| Q1 25 | $1.6B | $-334.1M | ||
| Q4 24 | $1.6B | $-301.3M | ||
| Q3 24 | $1.6B | $-311.3M | ||
| Q2 24 | $1.6B | $-321.7M | ||
| Q1 24 | $1.5B | $-330.5M |
| Q4 25 | $19.4B | $396.9M | ||
| Q3 25 | $17.8B | $396.1M | ||
| Q2 25 | $17.1B | $342.9M | ||
| Q1 25 | $16.6B | $327.2M | ||
| Q4 24 | $16.3B | $350.9M | ||
| Q3 24 | $16.0B | $389.5M | ||
| Q2 24 | $15.1B | $395.6M | ||
| Q1 24 | $15.1B | $438.8M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-925.5M | $74.6M |
| Free Cash FlowOCF − Capex | — | $74.6M |
| FCF MarginFCF / Revenue | — | 156.3% |
| Capex IntensityCapex / Revenue | 0.0% | 0.0% |
| Cash ConversionOCF / Net Profit | -40.92× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $127.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-925.5M | $74.6M | ||
| Q3 25 | $-290.4M | $47.6M | ||
| Q2 25 | $-210.5M | $-15.1M | ||
| Q1 25 | $-126.4M | $20.0M | ||
| Q4 24 | $-430.5M | $15.2M | ||
| Q3 24 | $-141.7M | $9.9M | ||
| Q2 24 | $-88.6M | $33.5M | ||
| Q1 24 | $-59.5M | $45.0M |
| Q4 25 | — | $74.6M | ||
| Q3 25 | — | $47.6M | ||
| Q2 25 | — | $-15.1M | ||
| Q1 25 | — | $19.9M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $9.9M | ||
| Q2 24 | — | $33.4M | ||
| Q1 24 | — | $44.9M |
| Q4 25 | — | 156.3% | ||
| Q3 25 | — | 39.0% | ||
| Q2 25 | — | -17.7% | ||
| Q1 25 | — | 48.4% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 10.8% | ||
| Q2 24 | — | 35.4% | ||
| Q1 24 | — | 60.0% |
| Q4 25 | 0.0% | 0.0% | ||
| Q3 25 | — | 0.0% | ||
| Q2 25 | — | 0.0% | ||
| Q1 25 | — | 0.1% | ||
| Q4 24 | 0.0% | 0.0% | ||
| Q3 24 | 0.0% | 0.0% | ||
| Q2 24 | 0.0% | 0.1% | ||
| Q1 24 | 0.0% | 0.1% |
| Q4 25 | -40.92× | — | ||
| Q3 25 | -9.84× | 1.19× | ||
| Q2 25 | -4.90× | -0.64× | ||
| Q1 25 | -3.99× | — | ||
| Q4 24 | -14.04× | 6.74× | ||
| Q3 24 | -8.76× | 2.71× | ||
| Q2 24 | -1.69× | — | ||
| Q1 24 | -2.21× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
